Literature DB >> 2516849

Lymphokine-activated killer induction and its regulation by macrophages in malignant pleural effusions.

H Yanagawa1, S Sone, A Nii, K Fukuta, M Nakanishi, K Maeda, M Honda, T Ogura.   

Abstract

Mononuclear cells (MNC) from pleural effusions and peripheral blood of 18 patients with primary lung cancer with malignant pleural effusion were studied. Pleural and blood MNC generated lymphokine-activated killer (LAK) activity similarly when cultured for 4 days with an optimal concentration of interleukin 2 (IL-2). Highly purified lymphocytes (greater than 98%) and monocyte-macrophages (greater than 90%) were isolated by discontinuous Percoll gradient centrifugation from pleural and blood MNC. Pleural macrophages, as well as blood monocytes, showed significant augmenting effects on in vitro LAK cell induction from pleural and blood lymphocytes by IL-2. During daily intrapleural administration of IL-2, significant induction of LAK activity in vivo was observed after 3 days, but then this LAK activity in pleural MNC decreased almost to zero by day 15. Daily injections of IL-2 resulted in reduction in the up-regulation of LAK induction by pleural macrophages and also in increases in the levels of soluble IL-2 receptors in pleural effusions. These findings indicate that in vivo LAK induction of lymphocytes in malignant effusions by IL-2 may be regulated by macrophages in the effusions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2516849      PMCID: PMC5917937          DOI: 10.1111/j.1349-7006.1989.tb01658.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


fetal bovine serum interleukin 2 IL‐2 receptor lymphokine‐activated killer mononuclear cells natural killer phosphate‐buffered saline
  29 in total

1.  Effect of Nocardia rubra cell wall skeleton on augmentation of cytotoxicity function in human pleural macrophages.

Authors:  M Sakatani; T Ogura; T Masuno; S Kishimoto; Y Yamamura
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Characterization and modulation of human lymphokine (interleukin 2) activated killer cell induction.

Authors:  M Hoyer; T Meineke; W Lewis; B Zwilling; J Rinehart
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

3.  The regulatory effect of adherent cells on lymphokine activated killer cells.

Authors:  Y Ibayashi; D S Hoon; S H Golub
Journal:  Cell Immunol       Date:  1987-12       Impact factor: 4.868

4.  Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine-activated killer cells.

Authors:  W L Crump; L B Owen-Schaub; E A Grimm
Journal:  Cancer Res       Date:  1989-01-01       Impact factor: 12.701

5.  Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  K Kato; T Yamada; K Kawahara; H Onda; T Asano; H Sugino; A Kakinuma
Journal:  Biochem Biophys Res Commun       Date:  1985-07-31       Impact factor: 3.575

6.  In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration.

Authors:  M T Lotze; M C Custer; S O Sharrow; L A Rubin; D L Nelson; S A Rosenberg
Journal:  Cancer Res       Date:  1987-04-15       Impact factor: 12.701

7.  Effects of human alveolar macrophages on the induction of lymphokine (IL 2)-activated killer cells.

Authors:  S Sone; T Utsugi; A Nii; T Ogura
Journal:  J Immunol       Date:  1987-07-01       Impact factor: 5.422

8.  Susceptibility of monocytes to lymphokine-activated killer cell lysis: effect of granulocyte-macrophage colony-stimulating factor and interleukin-3.

Authors:  J Y Djeu; R Widen; D K Blanchard
Journal:  Blood       Date:  1989-04       Impact factor: 22.113

9.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

10.  Killing of alveolar macrophages and of monocytes that have responded to granulocyte-macrophage colony-stimulating factor by human lymphokine-activated killer cells.

Authors:  S Sone; N Inamura; S M Singh; A Okubo; H Yanagawa; M Nakanishi; T Ogura
Journal:  Jpn J Cancer Res       Date:  1989-07
View more
  4 in total

1.  Prognostic value of CD4+ lymphocytes in pleural cavity of patients with non-small cell lung cancer.

Authors:  K Takahashi; S Saito; Y Kamamura; M Katakawa; Y Monden
Journal:  Thorax       Date:  2001-08       Impact factor: 9.139

2.  IL-6 in malignant pleural effusions and its augmentation by intrapleural instillation of IL-2.

Authors:  H Yanagawa; S Sone; M Munekata; S Atagi; A Nii; T Ogura
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

3.  Comparative analysis of interleukin 15 and interleukin 2 for induction of killer activity and of type 2 cytokine production by mononuclear cells from lung cancer patients.

Authors:  E Takeuchi; H Yanagawa; Y Suzuki; H Bando; S Sone
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

4.  Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion.

Authors:  K Takahashi; S Sone; S Saito; Y Kamamura; T Uyama; T Ogura; Y Monden
Journal:  Jpn J Cancer Res       Date:  1995-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.